Clear market notes built around the JSE, the rand, and what matters locally.

2026-10-11 08:26 • The Motley Fool Positive Axe Cap view: Selective

The market currently exhibits conflicting signals with investors experiencing fear (CNN Fear & Greed Index at 38) while valuation metrics like the Buffett Indicator (237%) and Shiller CAPE ratio suggest greed. Buffett's contrarian investing rule advises being fearful of overvalued growth stocks while seeking greedy opportunities in undervalued sectors like energy and healthcare. Success requires balancing both extremes rather than acting on a single indicator.

Axe note: Buffett’s 13-word rule guides us to be wary of overvalued shares but alert to bargains in beaten-down sectors.

2026-10-11 08:21 • The Motley Fool Positive Axe Cap view: Selective

Costco stock has fallen 14% from its May record to around $942. Historically, such drops have led to gains within a year in 7 of 9 instances since 2010, with a median return of 21%. September's comparable sales growth of 7.6% (up from 5.4% in August) suggests the slowdown has reversed. However, at 45x earnings, the current valuation resembles the 2022 drops that saw minimal gains, prompting the analyst to recommend gradual buying rather than aggressive investment.

Axe note: Costco shares have pulled back 14% from highs, historically a good entry point, though expensive multiples suggest measured exposure.

2026-10-11 08:11 • The Motley Fool Neutral Axe Cap view: Selective

Grail's stock surged 80% following a positive FDA panel vote on its Galleri multi-cancer early detection test. However, the article warns investors that while FDA approval and insurer adoption are important, the critical risk factor is the price insurers will be willing to pay for the $949 test, which depends on cost-benefit analyses and clinical data.

Axe note: Grail's multi-cancer test approval is positive but pricing debates could dampen upside.